NEW YORK (GenomeWeb News) – Entelos today said it has signed a contract with the Foundation for the National Institutes of Health Biomarkers Consortium to study and prioritize biomarkers of cardiovascular risk.

Under the terms of the contract, Entelos will use its Cardiovascular PhysioLab platform for the Biomarkers Consortium Atherosclerosis Project to perform computer simulations aimed at identifying those biomarkers that may be most effective at predicting cardiovascular disease and disease progression.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.

May
28
Sponsored by
PerkinElmer

This online seminar will demonstrate how RNA-seq analysis in a model organism can provide insights into human disease.